SOLENO THERAPEUTICS INC (SLNO) Fundamental Analysis & Valuation

NASDAQ:SLNO • US8342033094

Current stock price

52.695 USD
+0.02 (+0.05%)
Last:

This SLNO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. SLNO Profitability Analysis

1.1 Basic Checks

  • In the past year SLNO was profitable.
  • SLNO had a positive operating cash flow in the past year.
  • In the past 5 years SLNO reported 4 times negative net income.
  • SLNO had negative operating cash flow in 4 of the past 5 years.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.63%, SLNO belongs to the top of the industry, outperforming 89.92% of the companies in the same industry.
  • With an excellent Return On Equity value of 4.55%, SLNO belongs to the best of the industry, outperforming 90.31% of the companies in the same industry.
  • The Return On Invested Capital of SLNO (1.48%) is better than 88.37% of its industry peers.
Industry RankSector Rank
ROA 3.63%
ROE 4.55%
ROIC 1.48%
ROA(3y)-23.69%
ROA(5y)-49.77%
ROE(3y)-30.65%
ROE(5y)-99.65%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • SLNO has a better Profit Margin (10.75%) than 90.89% of its industry peers.
  • SLNO has a better Operating Margin (4.94%) than 88.76% of its industry peers.
  • SLNO has a better Gross Margin (98.58%) than 97.87% of its industry peers.
Industry RankSector Rank
OM 4.94%
PM (TTM) 10.75%
GM 98.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SLNO Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SLNO is destroying value.
  • SLNO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SLNO has more shares outstanding
  • SLNO has a better debt/assets ratio than last year.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • SLNO has an Altman-Z score of 14.32. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 14.32, SLNO belongs to the top of the industry, outperforming 85.08% of the companies in the same industry.
  • SLNO has a debt to FCF ratio of 1.07. This is a very positive value and a sign of high solvency as it would only need 1.07 years to pay back of all of its debts.
  • SLNO has a Debt to FCF ratio of 1.07. This is amongst the best in the industry. SLNO outperforms 94.19% of its industry peers.
  • SLNO has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.11, SLNO is doing worse than 63.76% of the companies in the same industry.
  • Even though the debt/equity ratio score it not favorable for SLNO, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.07
Altman-Z 14.32
ROIC/WACC0.15
WACC9.56%
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • SLNO has a Current Ratio of 5.80. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
  • SLNO's Current ratio of 5.80 is fine compared to the rest of the industry. SLNO outperforms 60.66% of its industry peers.
  • SLNO has a Quick Ratio of 5.55. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
  • SLNO's Quick ratio of 5.55 is in line compared to the rest of the industry. SLNO outperforms 59.30% of its industry peers.
Industry RankSector Rank
Current Ratio 5.8
Quick Ratio 5.55
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. SLNO Growth Analysis

3.1 Past

  • SLNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 105.40%, which is quite impressive.
EPS 1Y (TTM)105.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SLNO will show a very strong growth in Earnings Per Share. The EPS will grow by 244.30% on average per year.
  • SLNO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 74.50% yearly.
EPS Next Y1625.13%
EPS Next 2Y439.41%
EPS Next 3Y244.3%
EPS Next 5YN/A
Revenue Next Year149.64%
Revenue Next 2Y93.75%
Revenue Next 3Y74.5%
Revenue Next 5YN/A

3.3 Evolution

SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 2028 200M 400M 600M 800M 1B
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

7

4. SLNO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 229.11, which means the current valuation is very expensive for SLNO.
  • Based on the Price/Earnings ratio, SLNO is valued cheaply inside the industry as 88.57% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.95, SLNO is valued quite expensively.
  • With a Price/Forward Earnings ratio of 13.28, SLNO is valued correctly.
  • 97.29% of the companies in the same industry are more expensive than SLNO, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 38.68. SLNO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 229.11
Fwd PE 13.28
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SLNO is valued cheaper than 88.76% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, SLNO is valued cheaply inside the industry as 92.64% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 58.33
EV/EBITDA 195.36
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • SLNO's earnings are expected to grow with 244.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.14
PEG (5Y)N/A
EPS Next 2Y439.41%
EPS Next 3Y244.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SLNO Dividend Analysis

5.1 Amount

  • No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SLNO Fundamentals: All Metrics, Ratios and Statistics

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (4/21/2026, 12:56:55 PM)

52.695

+0.02 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-12
Inst Owners129.57%
Inst Owner Change-0.04%
Ins Owners1.54%
Ins Owner Change5.45%
Market Cap2.73B
Revenue(TTM)190.41M
Net Income(TTM)20.48M
Analysts86.32
Price Target68.14 (29.31%)
Short Float %16.67%
Short Ratio2.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)384.69%
Min EPS beat(2)10.35%
Max EPS beat(2)759.03%
EPS beat(4)3
Avg EPS beat(4)212.43%
Min EPS beat(4)-0.42%
Max EPS beat(4)759.03%
EPS beat(8)4
Avg EPS beat(8)75.61%
EPS beat(12)5
Avg EPS beat(12)42.49%
EPS beat(16)8
Avg EPS beat(16)34.88%
Revenue beat(2)2
Avg Revenue beat(2)18.07%
Min Revenue beat(2)1.56%
Max Revenue beat(2)34.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-40.32%
PT rev (3m)-39.57%
EPS NQ rev (1m)-2.22%
EPS NQ rev (3m)-3.98%
EPS NY rev (1m)-7.65%
EPS NY rev (3m)3.52%
Revenue NQ rev (1m)0.32%
Revenue NQ rev (3m)2.34%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)0.53%
Valuation
Industry RankSector Rank
PE 229.11
Fwd PE 13.28
P/S 14.31
P/FCF 58.33
P/OCF 58.24
P/B 6.05
P/tB 6.12
EV/EBITDA 195.36
EPS(TTM)0.23
EY0.44%
EPS(NY)3.97
Fwd EY7.53%
FCF(TTM)0.9
FCFY1.71%
OCF(TTM)0.9
OCFY1.72%
SpS3.68
BVpS8.7
TBVpS8.61
PEG (NY)0.14
PEG (5Y)N/A
Graham Number6.71101 (-87.26%)
Profitability
Industry RankSector Rank
ROA 3.63%
ROE 4.55%
ROCE 1.87%
ROIC 1.48%
ROICexc 3.78%
ROICexgc 3.87%
OM 4.94%
PM (TTM) 10.75%
GM 98.58%
FCFM 24.54%
ROA(3y)-23.69%
ROA(5y)-49.77%
ROE(3y)-30.65%
ROE(5y)-99.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.07
Debt/EBITDA 4.36
Cap/Depr 3.62%
Cap/Sales 0.04%
Interest Coverage 2.08
Cash Conversion 409.4%
Profit Quality 228.21%
Current Ratio 5.8
Quick Ratio 5.55
Altman-Z 14.32
F-Score7
WACC9.56%
ROIC/WACC0.15
Cap/Depr(3y)4.86%
Cap/Depr(5y)3.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.99%
EPS Next Y1625.13%
EPS Next 2Y439.41%
EPS Next 3Y244.3%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year149.64%
Revenue Next 2Y93.75%
Revenue Next 3Y74.5%
Revenue Next 5YN/A
EBIT growth 1Y105.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3701.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y167.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.73%
OCF growth 3YN/A
OCF growth 5YN/A

SOLENO THERAPEUTICS INC / SLNO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SOLENO THERAPEUTICS INC (SLNO) stock?

ChartMill assigns a fundamental rating of 5 / 10 to SLNO.


What is the valuation status of SOLENO THERAPEUTICS INC (SLNO) stock?

ChartMill assigns a valuation rating of 7 / 10 to SOLENO THERAPEUTICS INC (SLNO). This can be considered as Undervalued.


Can you provide the profitability details for SOLENO THERAPEUTICS INC?

SOLENO THERAPEUTICS INC (SLNO) has a profitability rating of 5 / 10.


What are the PE and PB ratios of SOLENO THERAPEUTICS INC (SLNO) stock?

The Price/Earnings (PE) ratio for SOLENO THERAPEUTICS INC (SLNO) is 229.11 and the Price/Book (PB) ratio is 6.05.